UniQure Pays US$10 M Upfront for Apic Bio’s ALS Gene Therapy

By Lucy Haggerty

Pharma Deals Review: Vol 2023 Issue 2 (Table of Contents)

Published: 15 Feb-2023

DOI: 10.3833/pdr.v2023.i2.2766     ISSN: 1756-7874

Section: Licensing



Adding another gene therapy to its portfolio, uniQure has entered into a licensing agreement with Apic Bio for APB-102, a one-time gene therapy for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details